MOLN Phase 2 readout: a negative outcome, -6.3%

On June 15, 2026, 4D-310 — MOLECULAR PARTNERS AG (Fabry Disease) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -6.3% in the window around the event. It had already run +7.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.